Search results
Pheon rides wave of ADC interest with $120M financing
BioPharma Dive via Yahoo Finance· 6 days agoCEO Cyrus Mozayeni said the company is taking a different approach than other developers of antibody...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoMultiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with
ASCO: With hopes high, Regeneron misses mark with just 1 complete response in solid tumor trial so...
FierceBiotech· 3 days agoRegeneron’s costimulatory bispecific antibody REGN7075 is being tested in patients with advanced...
InDevR Introduces Latest Solution for Influenza Vaccine Manufacturers, OmniFlu HA, to Simplify...
Morningstar· 4 days agoValidated, off-the-shelf kit for multiplexed seasonal hemagglutinin (HA) detection and quantification addresses the unique challenges faced by vaccine developers and manufacturers.BOULDER, CO ...
Hypothyroidism in teens: What to expect with an underactive thyroid
Medical News Today· 6 days agoHypothyroidism is when the thyroid gland produces too little thyroid-stimulating hormone (TSH). or...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 3 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Structural insights into the cross-exon to cross-intron spliceosome switch - Nature
Nature· 5 days agoCryo-electron microscopy structures of cross-exon pre-B and B-like complexes contribute new insights into the molecular mechanisms that mediate the switch from a cross-exon to a cross-intron organized spliceosome.
Why is immunotheraphy not being used as a tool in the war against Alzheimer's Disease?
Lohud | The Journal News via Yahoo News· 3 days agoThe drug slowed progression about 4 ½ months during the 18-month clinical trial compared to placebo....
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 6 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk ...
Clues From Bird Flu’s Ground Zero on Dairy Farms in the Texas Panhandle | naked capitalism
Naked Capitalism· 15 hours agoThe failures is the US response to the bird flu outbreak are piling up.
